Pharmacologically targeting molecular motor promotes mitochondrial fission for anti-cancer.
10.1016/j.apsb.2021.01.011
- Author:
Yi QIAN
1
;
Meimei ZHAO
1
;
Qinghua HAN
1
;
Jingkang WANG
1
;
Lixi LIAO
1
;
Heng YANG
1
;
Dan LIU
2
;
Pengfei TU
1
;
Hong LIANG
1
;
Kewu ZENG
1
Author Information
1. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
2. Proteomics Laboratory, Medical and Healthy Analytical Center, Peking University Health Science Center, Beijing 100191, China.
- Publication Type:Journal Article
- Keywords:
Anti-cancer;
CAM, chick embryo chorioallantoic membrane;
CETSA, cellular thermal shift assay;
Co-IP, co-immunoprecipitation;
DAPI, 4′,6-diamidino-2-phenylindole;
ER, endoplasmic reticulum;
HE, hematoxylin–eosin staining;
HSPA9;
HSPA9, heat-shock protein A9;
HUVEC, human umbilical vein endothelial cells;
IHC, immunohistochemistry;
LIHC, liver hepatocellular carcinoma;
Liver hepatocellular carcinoma;
MMP, mitochondrial membrane potential;
MYH9;
MYH9, myosin-9;
Mitochondrial fission;
Molecular motor;
SILAC, stable isotope labeling with amino acids in cell culture;
SPR, surface plasmon resonance;
Small molecule;
TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling;
Target identification
- From:
Acta Pharmaceutica Sinica B
2021;11(7):1853-1866
- CountryChina
- Language:English
-
Abstract:
Mitochondrial shape rapidly changes by dynamic balance of fusion and fission to adjust to constantly changing energy demands of cancer cells. Mitochondrial dynamics balance is exactly regulated by molecular motor consisted of myosin and actin cytoskeleton proteins. Thus, targeting myosin-actin molecular motor is considered as a promising strategy for anti-cancer. In this study, we performed a proof-of-concept study with a natural-derived small-molecule J13 to test the feasibility of anti-cancer therapeutics
